FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO
After missing a key secondary endpoint for its big osteoporosis drug romosozumab last fall and then running into a disturbing safety issue two months …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
